MedPath
Found 151 clinical trials|View Analysis
Sort by:

Pilot Study of EUS-Guided Radiofrequency and FOLFIRINOX in Advanced Pancreatic Cancer (RadioFAP )

Not Applicable
Not yet recruiting
Conditions
Pancreatic Adenocarcinoma
First Posted Date
2024-12-19
Last Posted Date
2024-12-19
Lead Sponsor
French Society of Digestive Endoscopy
Target Recruit Count
30
Registration Number
NCT06743386

Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC

Phase 3
Recruiting
Conditions
Locally Advanced Pancreatic Adenocarcinoma
Borderline Resectable Pancreatic Carcinoma
Pancreas Cancer
Neoadjuvant Chemotherapy
Surgery
Pancreatectomy
Interventions
Drug: FOLFIRINOX or gemcitabine-nab-paclitaxel
First Posted Date
2024-12-03
Last Posted Date
2024-12-03
Lead Sponsor
Sahlgrenska University Hospital, Sweden
Target Recruit Count
432
Registration Number
NCT06714604
Locations
🇸🇪

SahlgrenskaUH, Gothenburg, VGR, Sweden

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Phase 1
Active, not recruiting
Conditions
Metastatic Pancreatic Cancer
Interventions
First Posted Date
2024-08-05
Last Posted Date
2024-11-25
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
46
Registration Number
NCT06538207
Locations
🇯🇵

National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan

🇯🇵

Kanagawa Cancer Center, Yokohama-shi, Kanagawa, Japan

🇯🇵

Seirei Hamamatsu General Hospital, Hamamatsu-shi, Shizuoka, Japan

and more 6 locations

An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Phase 1
Active, not recruiting
Conditions
Metastatic Pancreatic Cancer
Interventions
First Posted Date
2024-08-01
Last Posted Date
2024-11-14
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
32
Registration Number
NCT06532344
Locations
🇯🇵

National Cancer Center Hospital, Chuo Ku, Japan

🇯🇵

Kanagawa Cancer Center, Yokohama-shi, Kanagawa, Japan

🇯🇵

National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan

and more 6 locations

Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer

Phase 2
Withdrawn
Conditions
Pancreatic Cancer Stage IV
Interventions
Drug: CPI-613, modified Folfirinox
First Posted Date
2024-07-24
Last Posted Date
2024-08-15
Lead Sponsor
Cornerstone Pharmaceuticals
Registration Number
NCT06518538
Locations
🇺🇸

Hirschfeld Oncology, Brooklyn, New York, United States

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

Phase 1
Not yet recruiting
Conditions
Pancreatic Adenocarcinoma
Metastatic Pancreatic Cancer
Basal Cell Neoplasm
Interventions
First Posted Date
2024-07-03
Last Posted Date
2025-01-10
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
104
Registration Number
NCT06483555
Locations
🇺🇸

University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment

Phase 2
Not yet recruiting
Conditions
Locally Advanced Pancreatic Adenocarcinoma
First Posted Date
2024-06-11
Last Posted Date
2024-11-14
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
43
Registration Number
NCT06453486

Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients

Recruiting
Conditions
Adjuvant Chemotherapy
First Posted Date
2024-04-29
Last Posted Date
2024-04-29
Lead Sponsor
HK inno.N Corporation
Target Recruit Count
36
Registration Number
NCT06389552
Locations
🇰🇷

Seoul ST. Mary's Hospital, Seoul, Korea, Republic of

Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5)

Phase 1
Not yet recruiting
Conditions
Borderline Resectable Pancreatic Cancer
Interventions
Drug: Pembrolizumab
Drug: Folfirinox
Radiation: SABR
First Posted Date
2024-04-25
Last Posted Date
2024-06-05
Lead Sponsor
Amsterdam UMC, location VUmc
Target Recruit Count
66
Registration Number
NCT06384560

The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma

Completed
Conditions
Pancreatic Cancer
Interventions
First Posted Date
2024-04-22
Last Posted Date
2024-04-22
Lead Sponsor
Luo Cong
Target Recruit Count
72
Registration Number
NCT06378580
Locations
🇨🇳

Zhejiang Province Cancer Hospital, Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath